Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Current Deferred Revenue (2022 - 2024)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Current Deferred Revenue for 3 consecutive years, with $31.8 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Current Deferred Revenue rose 159.45% year-over-year to $31.8 million, compared with a TTM value of $31.8 million through Dec 2024, up 159.45%, and an annual FY2024 reading of $31.8 million, up 159.45% over the prior year.
  • Current Deferred Revenue was $31.8 million for Q4 2024 at Kiniksa Pharmaceuticals International, up from $12000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $31.8 million in Q4 2024 and bottomed at $12000.0 in Q2 2024.
  • Average Current Deferred Revenue over 3 years is $9.1 million, with a median of $6.5 million recorded in 2023.
  • Peak annual rise in Current Deferred Revenue hit 159.45% in 2024, while the deepest fall reached 99.74% in 2024.
  • Year by year, Current Deferred Revenue stood at $12.0 million in 2022, then increased by 2.17% to $12.3 million in 2023, then soared by 159.45% to $31.8 million in 2024.
  • Business Quant data shows Current Deferred Revenue for KNSA at $31.8 million in Q4 2024, $12000.0 in Q2 2024, and $156000.0 in Q1 2024.